GHRS News and Press, GH Research PLC From 01/09/23

Initial approvals received for Phase 2b trial of GH001 in TRD (GH001-TRD-201), initiation of this trial expected in Q1 2023 Development of proprietary aerosol delivery device for GH001 progressed, IND submission with this device expected in Q3 2023 Phase 1 trial of GH002 in healthy volunt...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Throughout much of the new normal, the concept of short-squeeze stocks took off like wildfire. Essentially, this tactic centers on taking a contrarian bet against bearish traders in Wall Street’s version of playing...

GH Research press release ( NASDAQ: GHRS ): Q3 GAAP EPS of $0.00 beats by $0.17 . Cash was $256.9 million as of September 30, 2022, compared to $276.8 million as of December 31, 2021. Net loss was $0.4 million, or $0.008 loss per share, for the quarter ended Septem...

DUBLIN, Ireland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2022 an...

GH Research PLC (Nasdaq: GHRS) reported financial results for the second quarter ended June 30, 2022 and gave updates on its business. The company has no revenue at this time and is focused on developing its DMT drugs for mental health issues. The company also said it does not...

GH Research press release ( NASDAQ: GHRS ): Q2 GAAP EPS of $0.006. Cash was $265.4 million as of June 30, 2022, compared to $276.8 million as of December 31, 2021. The company believes that existing cash will be sufficient  to fund  operating expenses and cap...

DUBLIN, Ireland, Aug. 23, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2022 and ga...

GH Research press release (NASDAQ:GHRS): Q1 GAAP EPS of -$0.111. Cash was $270.8 million as of March 31, 2022, compared to $276.8 million as of December 31, 2021. For further details see: GH Research GAAP EPS of -$0.111

DUBLIN, Ireland, May 18, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the first quarter ended March 31, 2022 and gav...

GH Research press release (NASDAQ:GHRS): FY GAAP EPS of -$0.21 beats by $0.13. Cash was $276.8 million as of December 31, 2021, compared to $5.9 million as of December 31, 2020. For further details see: GH Research GAAP EPS of -$0.21 beats by $0.13